Vaughan Nelson Investment Management L.P. Boosts Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Vaughan Nelson Investment Management L.P. boosted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 24.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 329,010 shares of the company’s stock after purchasing an additional 64,360 shares during the period. Vaughan Nelson Investment Management L.P.’s holdings in TransMedics Group were worth $51,654,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of TMDX. International Assets Investment Management LLC bought a new position in shares of TransMedics Group in the second quarter worth about $47,000. USA Financial Formulas purchased a new stake in TransMedics Group in the 3rd quarter worth approximately $55,000. J.Safra Asset Management Corp raised its stake in TransMedics Group by 649.2% during the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after acquiring an additional 383 shares during the period. Signaturefd LLC lifted its holdings in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its position in shares of TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after purchasing an additional 316 shares during the period. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Down 8.9 %

Shares of TMDX opened at $80.48 on Friday. The stock has a market capitalization of $2.70 billion, a PE ratio of 85.62 and a beta of 2.08. The company’s fifty day moving average is $125.63 and its 200 day moving average is $139.09. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a fifty-two week low of $63.85 and a fifty-two week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same quarter last year, the firm earned ($0.12) earnings per share. The business’s quarterly revenue was up 63.7% on a year-over-year basis. Sell-side analysts expect that TransMedics Group, Inc. will post 1.07 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the transaction, the director now owns 732 shares in the company, valued at $61,158.60. The trade was a 90.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the completion of the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $8,180,642.53. This trade represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,958 shares of company stock worth $5,230,528. 7.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TMDX. Needham & Company LLC decreased their price objective on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. Oppenheimer decreased their price target on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a report on Tuesday, October 29th. Stephens upped their price objective on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Robert W. Baird cut their target price on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, October 29th. Finally, Piper Sandler reissued an “overweight” rating and issued a $180.00 price target on shares of TransMedics Group in a report on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $144.80.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.